A malleable sustained release formulation is created utilizing a local anesthetic wherein the composition is made sustained release by incorporating it into a bovine or porcine hemostatic agent. The composition is malleable enough to fit into a cavity such as a dental cavity and form the shape of the cavity. In addition to providing sustained release of the anesthetic, the composition also provides quicker reduction in bleeding.
A sustained release pharmaceutical formulation for pain management comprises an active ingredient, and a water-miscible and hygroscopic network-forming material, the active ingredient being dispersed within the water-miscible and hygroscopic network-forming material. The pharmaceutical may comprise a hydrophobic component, wherein the active ingredient dispersed within the water-miscible and hygroscopic network-forming material are together dispersed in hydrophobic component. Optionally, the pharmaceutical formulation may be combined with a reinforcing member for providing a system for sustained release of the pharmaceutical formulation for pain management.
A sustained release pharmaceutical formulation for pain management comprises an active ingredient, and a water-miscible and hygroscopic network-forming material, the active ingredient being dispersed within the water-miscible and hygroscopic network-forming material. The pharmaceutical may comprise a hydrophobic component, wherein the active ingredient dispersed within the water-miscible and hygroscopic network-forming material are together dispersed in hydrophobic component. Optionally, the pharmaceutical formulation may be combined with a reinforcing member for providing a system for sustained release of the pharmaceutical formulation for pain management.
A malleable sustained release formulation is created utilizing a local anesthetic wherein the composition is made sustained release by incorporating it into a bovine or porcine hemostatic agent. The composition is malleable enough to fit into a cavity such as a dental cavity and form the shape of the cavity. In addition to providing sustained release of the anesthetic, the composition also provides quicker reduction in bleeding.
A sustained release pharmaceutical formulation for pain management comprises an active ingredient, and a water-miscible and hygroscopic network-forming material, the active ingredient being dispersed within the water-miscible and hygroscopic network-forming material. The pharmaceutical may comprise a hydrophobic component, wherein the active ingredient dispersed within the water-miscible and hygroscopic network-forming material are together dispersed in hydrophobic component. Optionally, the pharmaceutical formulation may be combined with a reinforcing member for providing a system for sustained release of the pharmaceutical formulation for pain management.
A sustained release pharmaceutical formulation for pain management comprises an active ingredient, and a water-miscible and hygroscopic network-forming material, the active ingredient being dispersed within the water-miscible and hygroscopic network-forming material. The pharmaceutical may comprise a hydrophobic component, wherein the active ingredient dispersed within the water-miscible and hygroscopic network-forming material are together dispersed in hydrophobic component. Optionally, the pharmaceutical formulation may be combined with a reinforcing member for providing a system for sustained release of the pharmaceutical formulation for pain management.
A sustained release pharmaceutical formulation for pain management comprises an active ingredient, and a water-miscible and hygroscopic network-forming material, the active ingredient being dispersed within the water-miscible and hygroscopic network-forming material. The pharmaceutical may comprise a hydrophobic component, wherein the active ingredient dispersed within the water-miscible and hygroscopic network-forming material are together dispersed in hydrophobic component. Optionally, the pharmaceutical formulation may be combined with a reinforcing member for providing a system for sustained release of the pharmaceutical formulation for pain management.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development in the field of pain management; research and development in the field of sustained drug delivery; research and development in the field of drug encapsulation; research and development in the field of dental and oral surgery devices; research and development in the field of combination medical devices; research and development in the field of targeted drug therapy; pharmaceutical research and development; research and development in the field of micro-compounding; research and development in the field of pharmacokinetics; Providing research information in the field of pain management, sustained drug delivery, drug encapsulation, and dental and oral surgery devices
9.
MALLEABLE CONTROLLED RELEASE LOCAL ANESTHETIC WITH HEMOSTATIC COMPOSITION
The present invention is a malleable controlled release anesthetic combined with a hemostatic for packing in body cavity such as dental extraction cavity, a wound cavity or a surgical cavity.
A malleable sustained release formulation is created utilizing a local anesthetic wherein the composition is made sustained release by incorporating it into a bovine or porcine hemostatic agent. The composition is malleable enough to fit into a cavity such as a dental cavity and form the shape of the cavity. In addition to providing sustained release of the anesthetic, the composition also provides quicker reduction in bleeding.
The present invention relates to a method of delivering local anesthetic after dental extraction surgery. The present invention relates to packing the tooth socket with a tinned release local anesthetic which is coordinated with an initial local anesthetic and which lasts up to 5 days. The socket can be surgically sealed or the implant can act as the sealing means.
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/245 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques ayant un noyau aromatique lié au groupe carboxyle ayant un groupe amino ou nitro du type acide aminobenzoïque, p. ex. procaïne, novocaïne
